Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01997229 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)
A Phase 3 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 125
- Enrollment target
NCT01997229 is a Phase 3 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 125 participants.
The verdict
NCT01997229, a Phase 3 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 125 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if eculizumab is safe and effective for the treatment of refractory generalized Myasthenia Gravis.
Interventions
- DRUG Placebo
- BIOLOGICAL Eculizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2013-12 |
| Est. Completion | 2016-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01997229
The ClinicalTrials.gov registry entry for NCT01997229 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01997229 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01997229 about?
NCT01997229 is a clinical study titled "Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)". The purpose of this study is to determine if eculizumab is safe and effective for the treatment of refractory generalized Myasthenia Gravis.
What is the current status of trial NCT01997229?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 125 participants. The study started on 2013-12. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01997229?
The interventions under investigation include: Placebo (DRUG), Eculizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01997229?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.